RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Orchard Therapeutics Stock

Orchard Therapeutics Employees 2024

Orchard Therapeutics Employees

224

Ticker

ORTX

ISIN

US68570P1012

WKN

A2N8KD

In 2024, Orchard Therapeutics employed 224 people, a 0% change from the 224 number of employees in the previous year.

Orchard Therapeutics Aktienanalyse

What does Orchard Therapeutics do?

Orchard Therapeutics PLC is a biopharmaceutical company based in London. It was founded in 2015 and is traded on the NASDAQ and the London Stock Exchange. The company focuses on the development and commercialization of gene therapy products for rare and life-threatening diseases for which there is currently no cure. Orchard Therapeutics has its roots in the research and development of gene therapy products at the University College London (UCL) and the Great Ormond Street Hospital for Children (GOSH). The company has a strong partnership with these institutions and utilizes their resources for the development of new therapies. This close collaboration allows Orchard Therapeutics to focus on the research and development of gene therapy products for rare diseases. The business model of Orchard Therapeutics is to develop gene therapies for rare diseases that currently have no treatment options. These products are then licensed to pharmaceutical companies that are responsible for the production and marketing of the products. Orchard Therapeutics then receives a licensing fee and potential milestone payments for the sale of the products. Orchard Therapeutics has various divisions specializing in the development of gene therapies for different diseases. For example, the hemophilia division develops gene therapies for people with hemophilia, a genetic disease that impairs blood clotting. Other divisions focus on the development of gene therapies for muscular dystrophy, B-cell immunodeficiency, and chronic granulomatosis. The company has a broad portfolio of products currently in development. One of the most well-known products is "OTL-101," a gene therapy for the treatment of adenosine deaminase deficiency immunodeficiency (ADA-SCID), a severe type of immunodeficiency that can lead to infections and serious illness. Another important gene therapy is "OTL-103," which is used for the treatment of Wiskott-Aldrich syndrome (WAS), a rare genetic disorder that affects the immune system. Orchard Therapeutics manages to develop gene therapies for rare diseases by using a unique technology platform. This platform includes the use of lentiviruses that can insert genetic information into cells of the body. The gene therapies developed on this platform can help replace defective or missing genes with functional genes to treat diseases. Overall, Orchard Therapeutics is an emerging biotechnology company that focuses on the development of gene therapy products for rare and life-threatening diseases. The company has a strong partnership with leading medical institutions and utilizes a unique technology platform to develop gene therapies. With a wide range of products in development and potential groundbreaking therapies in the pipeline, Orchard Therapeutics is expected to play a significant role in the development of gene therapies for rare diseases. Orchard Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining Orchard Therapeutics's Employee Base

Orchard Therapeutics's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Orchard Therapeutics's operational capacity and future potential.

Year-to-Year Comparison

Assessing Orchard Therapeutics's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Orchard Therapeutics's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Orchard Therapeutics’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Orchard Therapeutics stock

How many employees does Orchard Therapeutics have this year?

Orchard Therapeutics has 224 undefined employees this year.

How many employees did Orchard Therapeutics have compared to the previous year?

Compared to the previous year, Orchard Therapeutics had 0% more employees.

What impact did the number of employees have on the company Orchard Therapeutics?

The number of employees has a direct impact on the efficiency and productivity of Orchard Therapeutics. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of Orchard Therapeutics?

The number of employees can also have an impact on investors of Orchard Therapeutics, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of Orchard Therapeutics affect the company?

An increase in equity of Orchard Therapeutics can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in Orchard Therapeutics's equity affect the company?

A reduction in equity of Orchard Therapeutics can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of Orchard Therapeutics?

Some factors that can influence the equity of Orchard Therapeutics include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of Orchard Therapeutics so important for investors?

The equity of Orchard Therapeutics is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at Orchard Therapeutics influence the company?

The number of employees at Orchard Therapeutics can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at Orchard Therapeutics evolved in recent years?

In recent years, the number of employees at Orchard Therapeutics has changed by 0.

How many employees does Orchard Therapeutics currently have?

Orchard Therapeutics currently has 224 undefined employees.

Why is the number of employees important for investors of Orchard Therapeutics?

The number of employees is important for investors of Orchard Therapeutics as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can Orchard Therapeutics take to change the number of employees?

To change the number of employees, Orchard Therapeutics can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does Orchard Therapeutics pay?

Over the past 12 months, Orchard Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Orchard Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Orchard Therapeutics?

The current dividend yield of Orchard Therapeutics is .

When does Orchard Therapeutics pay dividends?

Orchard Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Orchard Therapeutics?

Orchard Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Orchard Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Orchard Therapeutics located?

Orchard Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Orchard Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Orchard Therapeutics from 8/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/30/2024.

When did Orchard Therapeutics pay the last dividend?

The last dividend was paid out on 8/30/2024.

What was the dividend of Orchard Therapeutics in the year 2023?

In the year 2023, Orchard Therapeutics distributed 0 USD as dividends.

In which currency does Orchard Therapeutics pay out the dividend?

The dividends of Orchard Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Orchard Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Orchard Therapeutics

Our stock analysis for Orchard Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Orchard Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.